Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Eli Lilly Is Putting On Some Weight As Earnings Near
Eli Lilly and Company has shown rapid growth with significant revenue increases. Click here to find out why I've decided to keep LLY stock rated a hold.
Eli Lilly sues over knockoffs of signature weight loss drug, Zepbound
Eli Lilly sued three medical spas and online vendors for selling products that claim to contain the ingredient in its weight-loss medicine Zepbound.
Is Eli Lilly Still a Top Healthcare Stock After Its Blockbuster Drug Approval?
Pharmaceutical giant Eli Lilly and Company (LLY) is on an impressive run after winning Food and Drug Administration approval for a new eczema drug called Ebglyss. As the company expands its reach in the diabetes,
Lilly's weight loss drug shortage deemed over, but hurdles remain
Some patients fear tirzepatide, sold by Eli Lilly under the brand names Zepbound and Mounjaro, will be hard to get and prohibitively expensive once compounding pharmacies are no longer producing it.
MangoRx hits back at Eli Lilly’s weight loss drug copycat claims
MangoRx was responding to Eli Lily after the drugmaker sued it and two other medical spas and online vendors earlier this week for selling products claiming to contain tirzepatide
MM&M
20h
Senators question whether Eli Lilly, Pfizer telehealth platforms are inappropriately incentivizing prescriptions
As more Big Pharma companies have launched direct-to-consumer telehealth platforms, lawmakers have raised concerns they might ...
FiercePharma
1d
J&J, Eli Lilly pad immunology profiles with trial readouts in new patient groups
Key drugs from Johnson & Johnson and Eli Lilly stand to bolster their respective cases in competitive dermatology markets ...
STAT
1d
Eli Lilly weight loss drug shortage underscores deeper issues with FDA oversight
A turbulent series of events around the supply of Eli Lilly’s blockbuster weight loss treatment has raised concerns around ...
2d
on MSN
Lightning Round: Wait for a pullback in Eli Lilly to buy, says Jim Cramer
'Mad Money' host Jim Cramer weighs in on stock including: Viper Energy, Nextracker, Trump Media, Eli Lilly, and Dutch Bros.
2d
Cramer's Lightning Round: ‘Wait for a pullback' with Eli Lilly
Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to callers’ stock questions at ...
1d
Eli Lilly price target raised to $1,250 from $1,060 at Citi
Citi raised the firm’s price target on Eli Lilly (LLY) to $1,250 from $1,060 and keeps a Buy rating on the shares following a transfer of ...
10d
3 Reasons Eli Lilly Stock Isn't Going to Run out of Steam Anytime Soon
Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.
11d
How Eli Lilly Outpaces Nvidia—Here Is One Chart
Despite this, investors seem to have made up their one-track mind. Eli Lilly’s P/E ratio is more than double that of Novo ...
1d
Eli Lilly presents new Ebglyss data at FCD Conference
New results show Eli Lilly’s Ebglyss improved skin and itch among patients with moderate-to-severe atopic dermatitis who were previously treated with dupilumab. These results fr ...
1d
Lilly's Ebglyss shown to be effective in former Dupixent users
Eli Lilly (LLY) said a study of its drug Ebglyss showed it was able to improve skin and itch in patients with atopic ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
Pfizer
Alzheimer
United States Senate
Johnson & Johnson
National Health Service
Feedback